Roseomonas Mucosa Exopolysaccharide for Local Skin Immune Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases, such as cutaneous lupus erythematosus, psoriasis, and atopic dermatitis, often have poor efficacy and side effects, and there is a need for safe and low-toxicity therapies that can regulate immune responses and inflammation.

Innovation Solution

A live bacterial formulation and exopolysaccharide derived from Roseomonas mucosa, a skin commensal bacterium, are used to regulate immune microenvironments, inhibit inflammatory responses, and promote skin health by inhibiting B and T cell activation and macrophage polarization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (antimalarial drugs, topical glucocorticoids, calcineurin inhibitors) are used for cutaneous lupus erythematosus, then the treatment can be administered, but the curative effect is poor and side effects occur

Engineering Contradiction:

Improvecurative effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces skin commensal bacteria (Roseomonas mucosa, Staphylococcus hominis A9) and their exopolysaccharides as intermediary substances that mediate immune regulation. These bacteria and their metabolites act as natural modulators that inhibit B cell differentiation and reduce immune complex deposition, providing therapeutic effects without the severe side effects of conventional immunosuppressive drugs

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic approach from direct immunosuppression to immune modulation through probiotic bacteria and their exopolysaccharides. This parameter change in treatment mechanism leads to improved safety profile while maintaining efficacy in treating cutaneous lupus erythematosus, psoriasis, and atopic dermatitis

Inventive Principle:

Principle #35Parameter changes

2Reliability

If B cell depleting agents like CD20 monoclonal antibody are used, then remarkable curative effect is achieved in systemic lupus erythematosus, but the treatment complexity and cost increase

Engineering Contradiction:

Improvecurative effectVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces expensive monoclonal antibodies with cost-effective skin commensal bacteria and their exopolysaccharides. These natural products can be produced through simple fermentation processes and applied topically, significantly reducing treatment cost and complexity while maintaining therapeutic efficacy

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent utilizes the body's own skin microbiota (Roseomonas mucosa, Staphylococcus hominis A9) as the therapeutic source. These commensal bacteria naturally reside on the skin and can be activated to provide protective and regulatory functions, eliminating the need for external synthetic drugs and simplifying the treatment approach

Inventive Principle:

Principle #25Self-service

3Reliability

If systemic immunosuppressive drugs are used to treat autoimmune diseases, then immune response can be suppressed, but systemic side effects occur

Engineering Contradiction:

Improveimmune regulationVSAvoidsystemic side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies therapeutic bacteria and exopolysaccharides locally at the site of skin damage through topical application. This localized delivery ensures that immune modulation occurs primarily at the affected site, preventing systemic absorption and eliminating widespread side effects while maintaining effective local treatment

Inventive Principle:

Principle #3Local quality

4Reliability

If new therapies targeting B cells and immune responses are developed, then treatment efficacy can be improved, but safety and toxicity must be ensured

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the potentially harmful presence of skin commensal bacteria into a beneficial therapeutic resource. These bacteria, which naturally inhabit the skin, are harnessed to produce exopolysaccharides that regulate immune responses and treat autoimmune diseases, transforming a neutral or harmful factor into a beneficial treatment

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260000715A1Roseomonas mucosa, bacterial formulation and exopolysaccharide thereof, and preparation method therefor and application thereof

Publication Date: 2026.01.01 HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

AI summary

The invention discloses a Roseomonas mucosa, further discloses a bacterial formulation containing the Roseomonas mucosa above and an exopolysaccharide of the Roseomonas mucosa, and also discloses applications of the Roseomonas mucosa and the exopolysaccharide of the Roseomonas mucosa in prevention and/treatment of inflammation-related and/or T/B cell overactivation diseases, treatment or relief of cutaneous lupus erythematosus, treatment of psoriasis and atopic dermatitis, relief of UVB-induced skin damage, and preparation of a product for improving a skin condition. In the invention, a skin commensal bacteria strain is screened from skin of healthy people and has broad application prospects.